Adverse Drug Events Reporting News

Keeping Injectable Products in Cosmetic Dermatology Safe The rapid increase in intradermal injections of hyaluronic acid and Botox has been accompanied by an increase in side effects.
Medscape Medical News, December 26, 2023
'Real-time Experiment': Compounded GLP-1s on Coupon Site Purveyors on coupon sites like Groupon are marketing weight loss programs that include compounded semaglutide and tirzepatide.
Medscape Medical News, December 26, 2023
Many Patients With Type 2 Diabetes Stop Meds After a Year Often, patients with type 2 diabetes on second-line medication discontinue their therapy within a year, warn US researchers who highlight the need for new prescribing approaches.
Medscape Medical News, December 21, 2023
New Research Aims to Unravel Both ME/CFS and Long COVID A 2-day research conference sponsored by the US National Institutes of Health highlighted research that points to mechanisms that suggest potentially "druggable" pathways.
Medscape Medical News, December 21, 2023
Migraine Experts: Head-to-Head Drug Comparisons Better Placebo-controlled trials are insufficient for decisions that affect medication availability in EU member states.
Medscape Medical News, December 19, 2023
Restarting CGRPs for Migraine May Lower Response Rate Restarting a CGRP monoclonal antibody (mAb) after a gap in treatment may lower response rate, a new study suggests. However, switching to a different mAb may counter this effect.
Medscape Medical News, December 18, 2023
Thiazide Diuretics May Promote Hyponatremia The risk for hyponatremia was higher with thiazide drugs compared with nonthiazide drugs in older adults and patients with comorbidities.
Medscape Medical News, December 18, 2023
Structure's Diabetes Pill Misses Weight-loss Expectations in Mid-stage Trial Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of results from a similar treatment from rival Eli...
Reuters Health Information, December 18, 2023
One Fifth of Americans Report Use of Hemp-Derived Products Adults who used delta-8 THC were more likely to live in states where cannabis use is illegal.
Medscape Medical News, December 18, 2023
Compounders: Don't Listen to Bad Press on GLP-1s The compounding industry is trying to quell misconceptions about its GLP-1 products, which prescribers can order while branded versions of the drugs are in short supply.
Medscape Medical News, December 15, 2023
'We Will Rock You' Into Real-time Diabetes Control Rock music could offer patients with type 1 diabetes the means to stimulate insulin release and achieve real-time diabetes control via adapted pancreatic cells and speakers, suggests a novel study.
Medscape Medical News, December 15, 2023
Early Evidence Supports Psilocybin for Bipolar Depression An early trial suggests a combination of psilocybin and psychotherapy may be safe and effective for treatment-resistant depression associated with bipolar II disorder and deserves further study.
Medscape Medical News, December 15, 2023
Light Therapy a Beacon of Hope for Alzheimer's? A comprehensive meta-analysis shows that light therapy significantly improves sleep disorders and psychobehavioral symptoms in patients with Alzheimer’s disease.
Medscape Medical News, December 15, 2023
Navigating the Semaglutide Shortage Grappling with a shortage of obesity drugs, doctors find themselves at the forefront of strategic decision-making to ensure optimal patient care.
Medscape Medical News, December 14, 2023
GLP-1 RAs for CVD: Are Cardiologists Ready? The SELECT trial catapulted GLP-1 RAs into the forefront of CVD prevention, but cardiologists are making their own decisions about whether and how they might integrate these agents into practice.
Medscape Medical News, December 14, 2023
What if a Single GLP-1 Shot Could Last for Months? New hydrogel technology could reduce GLP-1 injections from daily or weekly to three times a year.
Medscape Medical News, December 14, 2023
'Baby Tam' Effective, Tolerable for Breast Cancer Prevention Lower-dose tamoxifen aims to reduce those side effects, but there remains some uncertainty about the minimum dose required to maintain efficacy.
MDedge News, December 13, 2023
Acne in Primary Care: The Best of Times? The repackaging of old medications into new formulations that are easier on the skin, and the availability of combination drug creams, should improve acne care.
Medscape Medical News, December 13, 2023
US Consumer Group Seeks Stronger Warnings on Botox, Similar Treatments Consumer advocacy group Public Citizen on Tuesday filed a petition with the U.S. Food and Drug Administration seeking to require makers of Botox and several similar...
Reuters Health Information, December 12, 2023
Distinct Toxicity Profiles for Anti-BCMA Myeloma Therapies CAR T cells directed against the B-cell maturation antigen (BCMA) are linked to systemic and neurological side effects, while the antibody teclistamab is associated with increased infection risk.
Medscape Medical News, December 11, 2023
ASH 2023 ASH 2023: Equity, Sickle Cell, and Real-Life Outcomes Health equity, sickle cell disease, and the thoughtful use of artificial intelligence and social media are among the key themes to be presented at the annual meeting of the American Society of Hematology.
MDedge News, December 04, 2023
Experimental Tx Restores Cognitive Function in Chronic TBI In a first-in-humans trial, deep brain stimulation restored executive function in five individuals with moderate to severe traumatic brain injury 3-18 years after injury.
Medscape Medical News, December 04, 2023
EU Watchdog Seeks More Safety Data From GLP-1 Drugmakers The EU's drug watchdog will request more data from makers of a class of diabetes and weight-loss drugs including Ozempic and Wegovy to further investigate suicidal thoughts in some patients taking them.
Reuters Health Information, December 01, 2023
Pfizer Drops Twice-Daily Version of Obesity Pill Over Side Effects Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting.
Reuters Health Information, December 01, 2023
EMA Committee Recommends Label Update for Some Decongestants The European Medicines Agency's safety committee on Friday recommended changes to product information for all medicines that contain the ingredient pseudoephedrine to address safety concerns related to neurological and heart-related side effects.
Reuters Health Information, December 01, 2023
No Adverse Effects From Steroids in Pregnant Women With EoE 'Our recommendations about the use of steroids among this population are based on the safety data extrapolated mainly from pregnant women with asthma.'
MDedge News, December 01, 2023
What Is the Dark Side of GLP-1 Receptor Agonists? Doctors who prescribe this class of medication should be aware of the rare side effects with which it is associated, said an obesity expert.
Medscape Medical News, December 01, 2023
Meta-Analysis: Suicide Risk Not Increased With Isotretinoin In fact, those treated with the drug for severe acne may have a lower risk for suicide attempts 2-4 years after treatment, according to the study authors.
MDedge News, December 01, 2023
Avoid Anti-HER2 Cancer Therapies During Pregnancy Women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates.
Medscape Medical News, November 29, 2023
Alert FDA Warns of Potentially Lethal Reaction to Seizure Meds Levetiracetam and clobazam can cause a rare but serious drug reaction with eosinophilia and systemic symptoms that can be life threatening if not diagnosed and treated quickly, the FDA warns.
Medscape Medical News, November 28, 2023
Alert FDA OKs New Agent to Block Chemotherapy-Induced Neutropenia The new colony-stimulating factor from China proved comparable to pegfilgrastim (Neulasta) in clinical testing.
Medscape Medical News, November 28, 2023
EADV 2023 At 52 Weeks, Hair Growth Still Climbing on Deuruxolitinib With response curves still climbing at follow-up to date, the results are 'truly, truly remarkable.'
MDedge News, November 28, 2023
AANEM 2023 Novel Myasthenia Gravis Therapies Bring Opportunities New treatments for myasthenia gravis are bringing new promise to patients, but their use must be balanced against short-term and long-term risks.
MDedge News, November 27, 2023
Metoclopramide Nasal Spray Eases Gastroparesis in Women A nasal spray formulation of metoclopramide was well tolerated and reduced symptoms of diabetic gastroparesis in women with moderate to severe baseline symptoms in a phase 3 study
Medscape Medical News, November 27, 2023
Circadian Calorie-Burning Cycles Altered in Obesity Among people with obesity, the lowest point of energy expenditure is not during sleeping hours, as seen in those without obesity.
Medscape Medical News, November 21, 2023
AHA 2023 Single Injection Reduces Blood Pressure for 6 Months The RNA interference therapeutic targeting synthesis of angiotensinogen lowered BP in adults with mild to moderate hypertension for up to 6 months after one dose in the phase 2 KARDIA-1 study.
Medscape Medical News, November 20, 2023
FDA Panel Flags Insufficient Data for Chronic Cough Drug Advisers to the FDA said that data on Merck's chronic cough drug do not provide sufficient evidence to prove its clinical benefit for patients.
Reuters Health Information, November 17, 2023
FDA Panel Voices Concerns Over Two Lymphoma Rushed Approvals 'The consensus of the advisory committee is that we have significant concerns about the very prolonged delay and getting these confirmatory studies underway.'
MDedge News, November 17, 2023
New Consensus Guide on Rare Drug Hypersensitivity Reaction Experts provided parameters to help clinicians, but they acknowledged the limited evidence base for drug reaction with eosinophilia and systemic symptoms.
Medscape Medical News, November 17, 2023
AHA 2023 More Evidence of Better Outcomes With 120 mm Hg BP Target Intensive lowering of blood pressure to a systolic target < 120 mm Hg reduced cardiovascular events among high-risk individuals by 12% vs a target < 140 mm Hg in the ESPRIT trial.
Medscape Medical News, November 16, 2023

No Results